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Introduction
 Breast cancer is the most common cancer among 
women worldwide, with an estimated 1.38 million new 
cases diagnosed in 2008 (23% of all cancers), and is the 
leading cause of cancer death (458,000 deaths) (Ferlay 
et al., 2010). Incidence rates vary from 19.3 per 100,000 
women in Eastern Africa to 89.9 per 100,000 women in 
Western Europe, and are high (greater than 80 per 100,000) 
in developed regions of the world and low (less than 40 
per 100,000) in most of the developing regions. Although 
the incidence of breast cancer in Asian countries is still 
lower than in Western countries, the incidence among 
Asian women has been rising rapidly (Jemal et al., 2011). 
 Although breast cancer is the most frequently diagnosed 
cancer in women in the Republic of Korea (15.1% of all 
cancer diagnoses in 2007), the incidence of breast cancer 
(34.7 per 100,000) (Jung et al., 2010) is still lower than 
in Western countries (e.g., 76.7 per 100,000 among North 
Americans) (Ferlay et al., 2010). However, the incidence 
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Abstract
 Breast cancer is the most commonly diagnosed cancer among women in the Republic of Korea. However, many 
women are not aware of the importance of on-schedule mammography screening for breast cancer. The objectives 
of this study were to estimate the percentage of women that attended on-schedule mammography rescreening, 
and to examine the factors associated with rescreening, among the target screening population (women aged 
≥40 years) in Korea. The study population was derived from the National Health Insurance (NHI) Corporation 
database for the National Cancer Screening Program (NCSP), and included 2,511,976 women from the target 
screening population who attended the NCSP for breast cancer in 2005-2006 (baseline). Study participants were 
followed-up to determine whether they attended mammography rescreening after 2 years as recommended. 
Among those who attended mammography screening in 2005-2006, 61.3% were rescreened on schedule 2 years 
later. The odds of being rescreened were the highest in study participants aged 60-69 years. NHI beneficiaries 
with a higher premium were significantly more likely to be rescreened than Medical Aid Program recipients. 
A false-positive screening result at baseline adversely affected subsequent screening behavior. Furthermore, 
those who had a history of mammography screening before baseline were more likely to return for rescreening. 
Therefore, assessment of a woman’s screening history and socioeconomic status, in combination with interventions 
to reduce anxiety, such as involving primary care physicians or better informing women about breast cancer 
and mammography screening, are needed. Efforts to reduce false-positive results and improve the quality of 
mammography may also increase compliance with breast cancer screening recommendations.  
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of breast cancer in Korea has been rapidly increasing 
(annual percent change=6.6% per year between 1999 and 
2007) (Jung et al., 2010) and the rate of increase seems to 
be much higher than that in European countries (annual 
percent change=0.8–3.0% per year) (Botha et al., 2003; 
Keegan et al., 2007). To reduce the burden of breast cancer, 
the Korean Government and National Health Insurance 
Corporation (NHIC) introduced a mammography-based 
nationwide breast cancer screening program as a part of 
the National Cancer Screening Program (NCSP) (Kim et 
al., 2011). When the program began in 1999, the NCSP 
for breast cancer offered free-of-charge mammography 
screening to Medical Aid Program (MAP) recipients 
only. In 2002 the NCSP expanded the program to include 
National Health Insurance (NHI) beneficiaries in the 
lowest 20% income bracket, and in 2005 it included 
all NHI beneficiaries with a premium 50% or under of 
the NHIC full premium rate. Currently, MAP recipients 
and NHI beneficiaries with premiums 50% or under can 
receive mammography screening without any out-of-
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pocket expense. NHI beneficiaries with premiums over 
50% can receive breast cancer screening with a 10% out-
of-pocket expense. The NCSP recommends that women 
40 years of age and over attend mammography screening 
every 2 years (Kim et al., 2011) and at the beginning of 
each year all women in this age group receive an invitation 
letter from the NHIC. 
 Regular screening has been shown to reduce long-term 
cancer mortality for a number of different cancer sites 
(Smith et al., 2003; 2010). Previous studies have shown 
that breast cancer screening can reduce corresponding 
mortality rates by 25%-30% (IARC: World Cancer 
Report,2003). Despite these benefits, according to the 
2008 Annual Report of the NCSP, the participation rate 
for mammography screening was only 35.0% in Korea 
(Lim et al., 2010). An important issue related to the 
early detection of cancer is the extent to which patients 
continue to use screening services after receiving an initial 
examination. Despite the importance of attending breast 
cancer screening at recommended intervals, relatively 
little known about the factors associated with on-schedule 
mammography rescreening. 
 An important goal of screening programs is not only 
to achieve high participation rates, but also to maintain 
these high rates at each subsequent screening round 
(O’Sullivan, Sutton, Dixon, et al., 2001). Therefore, it is 
just as important to understand why some women come 
back for rescreening, whereas others do not, as it is to 
understand why women attend in the first place. Although 
some of the factors associated with initial screening 
attendance may be similar to those associated with 
rescreening attendance, we cannot automatically assume 
that the same factors are relevant at different screening 
rounds. One issue that may be especially important when 
women are considering rescreening is whether they have 
had a previous positive mammography screening result, 
which, after further assessment, revealed a non-malignant 
condition (false-positive). 
 In view of the importance of achieving high 
participation rates at all recommended screening rounds 
in reducing breast cancer mortality, this study examined 
the factors associated with rescreening attendance at 
recommended intervals. In particular, we considered 
the potential effects of previous false-positive screening 
results on subsequent screening behavior.
 
Materials and Methods
Study population 
 The major data source for this study was the NHIC 
database for the NCSP. Data were collected from 2005 to 
2008 for the target screening population of the NCSP for 
breast cancer. Selection of study participants was carried 
out in two steps as described in Figure 1. First, the study 
population was restricted to the target screening population 
invited through the NCSP for breast cancer between 
January 1, 2005 and December 31, 2006. Among those 
invited during this period, 2,885,448 women attended 
mammography screening in 2005 and 2006 (baseline). 
Second, to estimate the rescreening participation rate, we 
excluded 1) 313,995 women who were not eligible for 
rescreening 2 years after baseline due to death, relocation, 
etc.; 2) 4,578 women diagnosed with breast cancer after 
baseline (both true-positive and false-negative cases), 
based on information from the Korean National Cancer 
Incidence database (KNCIDB), which contains 95% of 
newly diagnosed malignancies in Korea (Won et al., 2009). 
This left 2,536,915 women (88.8% of those screened at 
baseline) who were invited to breast cancer screening 
again in 2007 and 2008. Finally, we excluded 24,939 
otherwise eligible women with missing values for some of 
the variables needed for this study. Therefore rescreening 
behavior was examined in a final study population of 
2,511,976 participants (Figure 1). 
Study variables
 The NHIC database for the NCSP includes information 
on age, gender, health insurance type (MAP, NHI), breast 
cancer screening date, and screening results. We used 
health insurance type and health insurance premium 
as a proxy for socioeconomic status (Liberator et al., 
1998; Marcin et al., 2003). Based on this information, 
we classified the participants into three groups: MAP 
recipients; NHI beneficiaries with a premium 50% or 
under; and NHI beneficiaries with a premium over 50%. 
Mammography screening results were reported in four 
categories (negative, benign, suspicious, highly suggestive 
of malignancy). The mammography results were defined 
as positive if they were categorized as ‘suspicious’ or 
‘highly suggestive of malignancy’. The categories of 
‘negative’ and ‘benign’ were defined as negative. To 
confirm the accuracy of mammography screening at 
baseline, we ascertained whether study participants 
had been subsequently diagnosed with breast cancer 
through linkage with the KNCIDB. After excluding 
study participants who developed breast cancer, baseline 
screening accuracy was evaluated as follows: screening 
results of ‘negative’ and ‘benign’ were classified as true-
negatives, and ‘suspicious’ and ‘highly suggestive of 
malignancy’ were classified as false-positives.
 We also collected information on history of 
mammography screening to confirm whether previous 
screening was correlated with subsequent screening 
behavior. This information was obtained through linkage 
with the NCSP database from 2002-2004, and was 
Figure 1. Participant Selection Process
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Table 1. Descriptive Information for the Study 
Population at Baseline, Korean National Cancer 
Screening Program for Breast Cancer, 2005-2006
                          n            (%)
Total  2,511,976 
Age (years)  
  40-49 913,628 36.4
  50-59  808,916 32.2
  60-69 544,780 21.7
  ≥70 244,652 9.7
Health insurance type  
  MAP 160,420 6.4
  NHI (premium under 50%) 1,339,032 53.3
  NHI (premium over 50%) 1,012,524 40.3
Screening results   
  Negative 1,677,973 66.8
  Benign 561,493 22.4
  Suspicious 272,391 10.8
  Highly suggestive of malignancy 119 0.0
Accuracy of mammography   
  True-negative  2,239,466 89.1
  False-positive 272,510 10.9
History of mammography screening  
  Never invited before baseline† 163,890 6.5
  Previously invited but not screened‡ 1,525,589 60.7
  Previously screened§  822,497 32.8
Year recruited  
   2005 1,057,452 42.1
   2006 1,454,524 57.9
MAP, medical aid program; NHI, national health insurance; 
n, number, †Women who had never been invited, nor screened 
before baseline, ‡Women who had been invited, but did not 
attend screening before baseline, §Women who had been 
invited and attended screening once or more before baseline.
Table 2. Characteristics of the Study Population According to Rescreening Status in 2007-2008  
Rescreening                   Yes, n                   (%)                   No, n       (%)               p-value 
Total 1,539,814 (61.3) 972,162 (38.7) 
Age (years)     
 40-49 513,553 (56.2) 400,075 (43.8) <0.001
 50-59  537,760 (66.5) 271,156 (33.5) 
 60-69 362,061 (66.5) 182,719 (33.5) 
 ≥70 126,440 (51.7) 126,440 (48.3) 
Health insurance type     
 MAP 75,187 (46.9) 85,233 (53.1) <0.001
 NHI (premium under 50%) 830,859 (62.1) 508,173 (37.9) 
 NHI (premium over 50%) 633,768 (62.6) 378,756 (37.4) 
Screening results at baseline     
 Negative 1,044,871 (62.3) 633,102 (37.7) <0.001
 Benign 334,526 (59.6) 226,967 (40.4) 
 Suspicious 160,358 (58.9) 112,033 (41.1) 
 Highly suggestive of malignancy 59 (49.6) 60 (50.4) 
Accuracy of mammography at baseline     
 True-negative 1,379,397 (61.6) 860,069 (38.4) <0.001
 False-positive 160,417 (58.9) 112,093 (41.1) 
History of mammography screening     
 Never invited before baseline† 83,868 (51.2) 80,022 (48.8) <0.001
 Previously invited but not screened‡ 862,793 (56.6) 662,796 (43.4) 
 Previously screened§  593,153 (72.1) 229,344 (27.9) 
Year recruited     
 2005  617,733 (58.4) 439,719 (41.6) <0.001
 2006 922,081 (63.4) 532,443 (36.6) 
MAP, medical aid program; NHI, national health insurance; n, number., †Women who had never been invited, nor screened before 
baseline, ‡Women who had been invited, but did not attend screening before baseline, §Women who had been invited and attended 
screening once or more before baseline.
categorized into one of the following groups for all study 
participants: (a) never invited before baseline (women 
who had never been invited nor screened before baseline); 
(b) previously invited but not screened (women who had 
been previously invited, but did not attend screening 
before baseline); (c) previously screened (women who 
had been invited, and attended screening once or more 
before baseline). 
Statistical analysis
 Descriptive analyses were carried out for age, health 
insurance type, screening results at baseline, accuracy of 
mammography at baseline, and rescreening rate. Bivariate 
analyses 
Results 
Characteristics of the study population
 Table 1 presents descriptive data for the study 
population of 2,511,976 women (as described in Figure 
1). Women aged 40-49 years comprised more than one-
third of total study population, and NHI beneficiaries with 
a premium under 50% represented more than half of the 
total study population. Most screening results at baseline 
were true-negatives (89.1%) (Table 1). 
On-schedule rescreening rate 
 Among study participants who attended breast cancer 
screening in 2005-2006, 61.3% attended rescreening in 
2007-2008 (Table 2). In bivariate analyses, women 50-69 
years old were more likely to be rescreened (p <0.001). 
Among health insurance types, NHI beneficiaries with 
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a premium over 50% showed the highest rescreening 
rate (p <0.001). Study participants with screening 
results of ‘benign’, ‘suspicious’, or ‘highly suggestive of 
malignancy’ at baseline were less likely to be rescreened, 
as were those who had a false-positive result at baseline 
(p <0.001). Regarding history of mammography 
screening, women who attended screening once or more 
before baseline were more likely to be rescreened than 
either those for whom baseline was their first screening 
invitation, or those who had been previously invited but 
did not attend screening before baseline (p <0.001). The 
rescreening rate slightly increased in 2008; 63.4% of 
women who attended breast cancer screening in 2006 
were rescreened in 2008. 
Factors associated with on-schedule mammography 
rescreening for breast cancer 
 Factors most predictive of on-schedule breast cancer 
screening were explored using a logistic regression model 
at baseline (Table 3). Overall, the odds of attending 
rescreening were the highest in study participants aged 
60-69 years old. Those with a NHI premium over 50% 
were significantly more likely to be rescreened than MAP 
recipients (adjusted odds ratio [OR]=1.97, 95% confidence 
interval [CI]=1.95–1.99). In addition, those who attended 
screening once or more before baseline were significantly 
more likely to attend rescreening (adjusted OR=2.02, 
95% CI=2.00–2.05). Women who had a false-positive 
screening result at baseline were statistically significantly 
less likely to attend rescreening (adjusted OR=0.92, 95% 
CI=0.91–0.93). 
 
Discussion
The present study estimated the on-schedule 
rescreening rate as per recommended screening intervals 
in an average-risk population in Korea; 61.3% of 
participants were rescreened on-schedule. This is lower 
than the participation rate for breast cancer screening 
among population-based samples in Western countries 
(Gilliland et al., 2000; O’Byrne et al., 2000; Pinckney 
et al., 2003; Bobo et al., 2004). For example, in 1997, 
on-schedule mammography rescreening rates for breast 
cancer were between 72.4 and 81.5% in the US National 
Breast and Cervical Cancer Early Detection Program 
(NBCCEDP) (Bobo et al., 2004). However, this high 
rescreening rate may be explained by the fact that the 
NBCCEDP offers free screening to low-income women. 
In this study, we divided health insurance recipients into 
three types: MAP recipients, NHI beneficiaries with a 
premium 50% or under, and NHI beneficiaries with a 
premium over 50%, and these three groups served as a 
proxy for socioeconomic status. In contrast to the results 
of the NBCCEDP, low-income women in Korea (MAP 
recipients) were less likely to attend rescreening for 
breast cancer than NHI beneficiaries, despite the fact 
that it is free of charge. As determined by multivariate 
logistic regression, MAP recipients were less likely to 
attend rescreening for breast cancer. These results are not 
limited to Korea; in other countries as well people with 
lower socioeconomic status are less likely to participate 
in screening programs (Song and Fletcher, 1998; Bobo 
et al., 2004; 2006), underlining the need for continuous 
efforts to reduce the socioeconomic disparities in the use 
of screening programs. 
Several studies have investigated the potential 
effects of a false-positive screening result on subsequent 
screening behavior. Some studies reported that an initial 
false-positive screening result did not discourage women 
from being rescreened (Burman et al., 1999; O’Sullivan 
et al., 2001; Pinckney et al., 2003). In fact, women with 
a false-positive result were more likely to return (Katz et 
al., 2000; O’Sullivan et al., 2001; Pinckney et al., 2003). 
Indeed, women who have had a false-positive screening 
result have higher levels of anxiety about breast cancer 
than other women do, and therefore have a higher stated 
intention of being rescreened at recommended intervals 
(Gram et al., 1990; Lerman et al., 1991). In contrast, the 
current study showed that women with a false-positive 
screening result at baseline were less likely to return 
for rescreening at recommended intervals than those 
with true-negative results (OR=0.92, 95% CI=0.91-
0.93), and similar results have been reported in several 
previous studies (Johnson et al., 1996; McCann et al., 
2002; Chiarelli et al., 2003; Hofvind et al., 2003; Alamo-
Junquera et al., 2011; Seigneurin et al., 2011). The 
uncertainty that occurs during the screening process while 
a woman is waiting for the results of additional testing 
Table 3. Results of Logistic Regression for Factors 
Influencing Rescreening for Breast Cancer 
(n=2,511,976)
                           Crude OR                Adjusted OR   
            (95% CI)                   (95% CI)  
Age (years)    
 40-49 1.00 Reference 1.00 Reference
 50-59  1.55 (1.54-1.55) 1.45 (1.44-1.46)
 60-69 1.54 (1.53-1.55) 1.51 (1.50-1.52)
 ≥70 0.83 (0.83-0.84) 0.90 (0.90-0.91)
Health insurance type    
 MAP 1.00 Reference 1.00 Reference
 NHI 1.85 (1.83-1.87) 1.91 (1.89-1.93)
  (premium under 50%)
 NHI 1.90 (1.88-1.92) 1.97 (1.95-1.99)
  (premium over 50%)
Accuracy of mammography at baseline   
 True-negative  1.00 Reference 1.00 Reference
 False-positive 0.89 (0.88-0.90) 0.92 (0.91-0.93)
History of mammography screening   
 Never invited 1.00 Reference 1.00 Reference
  before baseline†
 Previously 1.24 (1.23-1.26) 1.01 (1.00-1.03)
  invited but not screened‡
 Previously screened§  2.47 (2.44-2.49) 2.02 (2.00-2.05)
Year recruited    
 2005  1.00 Reference 1.00 Reference
 2006 1.23 (1.23-1.24) 1.19 (1.19-1.20)
MAP, medical aid program; NHI, national health insurance; 
OR, odds ratio; CI, confidence interval, †Women who had 
never been invited, nor screened before baseline, ‡Women who 
had been invited, but did not attend screening before baseline, 
§Women who had been invited and attended screening once or 
more before baseline
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performed as a consequence of a positive mammography 
screening result may produce more worries than a 
negative, or clearly positive result (Marteau, 1994). Some 
of the discrepancy between studies surrounding the effect 
of a false-positive result on subsequent screening behavior 
could be due to the differences in breast cancer screening 
policies between countries. Many European countries 
have organized population-based screening programs, but 
the populations are gleaned from the patients of general 
physicians or family doctors. In the Korean NCSP, the 
involvement of a family doctor or general physician in 
the screening process is very limited. Mammography is 
performed at a clinic or hospital that has been designated 
as a breast cancer screening unit. Any clinic, hospital, or 
specific screening facility can apply to be certified as a 
breast cancer screening unit, and those who are invited to 
attend screening can visit any of these certified screening 
units. The lack of a close relationship or continuous 
connection between a physician in the breast cancer 
screening unit and participants, which does exist between 
a family doctor and their patients, might have affected 
the low rescreening rate among women who had false-
positive results.  
In the present study, we also found that age and 
history of mammography screening were associated 
with on-schedule rescreening. Specifically, women 
aged 70 years or over were less likely to be rescreened 
than women aged 40-69 years. In the NCSP, there is no 
age limit for breast cancer screening. All women in the 
target population receive an invitation letter from the 
NHIC at the beginning of the year. Therefore, the lower 
rescreening rate among women aged 70 or over may be 
due to a hesitancy to follow the recommendation for 
breast cancer screening. Also, it may be more difficult 
for the elderly to understand the need to attend regular 
breast cancer screening. Previous studies have shown 
that clinicians often fail to discuss key information about 
breast cancer screening with older women. Interestingly, 
previous mammography screening was strongly associated 
with rescreening in the present study. Compared with 
people who had never been invited nor screened before 
baseline, women who had been invited and screened once 
or more before baseline were significantly more likely to 
be rescreened (OR=2.02, CI=2.00–2.05). These results 
suggest that previous experience with mammography 
screening positively influences subsequent screening 
behavior. We also observed an effect of study period on 
rescreening. The levels of rescreening were 58.4% in 2007 
and 63.4% in 2008. A future study to examine time trends 
in rescreening is therefore highly recommended. 
A number of limitations should be considered 
when interpreting these results. Although the NCSP is 
a nationwide population-based screening program, it 
cannot take into account screening performed outside 
the NCSP, as the NCSP does not capture tests carried out 
in the private sector (e.g., opportunistic screening). In 
addition, other factors that influence screening were not 
considered in this study, such as psychological factors 
(e.g., discomfort, embarrassment, fear of the results, or 
complication concerns) and socioeconomic factors besides 
income (e.g., education, occupation).
Despite these limitations, to our knowledge, this 
is the largest study performed to-date that assesses the 
effect of a false-positive breast cancer screening result 
on attendance at the next recommended screening 
round and takes women’s personal characteristics into 
account. A better understanding of the factors that affect 
rescreening is fundamental if we are to increase the 
impact of breast cancer screening. In this study, 61.3% 
of women were rescreened on schedule, which is lower 
than the rate in Western countries. Although the NCSP 
for breast cancer in Korea has different policies, efforts 
to improve the rescreening rate are nevertheless needed. 
Our study results also highlight that having a false-positive 
screening result negatively affects subsequent screening 
behavior. Given the frequency of false-positive results, 
the corresponding deterrence from screening could be a 
serious public health problem in Korea. Therefore, it may 
be necessary to assess a woman’s screening history, and 
socioeconomic status, in combination with interventions 
to reduce anxiety, such as involvement of primary care 
physicians or providing information to women about 
breast cancer and screening. Furthermore, efforts to 
reduce false-positive results and improve the quality of 
mammography may increase compliance with breast 
cancer screening recommendations. Our results could 
be useful to improve the screening process and increase 
compliance with this program.
 
Acknowledgements 
This study was supported by a Grant-in-Aid for Cancer 
Research and Control from the National Cancer Center, 
Korea (Grant number: 1010200). The authors have no 
conflict of interest.
References
Alamo-Junquera D, Murta-Nascimento C, Macia F, et al (2011). 
Effect of false-positive results on reattendance at breast 
cancer screening programmes in Spain. Eur J Public Health.
Bobo JK, Shapiro JA, Brustrom J (2006). Efforts to locate low-
income women for a study on mammography rescreening: 
implications for public health practice. J Community Health, 
31, 249-61.
Bobo JK, Shapiro JA, Schulman J, et al. (2004). On-schedule 
mammography rescreening in the National Breast and 
Cervical Cancer Early Detection Program. Cancer Epidemiol 
Biomarkers Prev, 13, 620-30.
Botha JL, Bray F, Sankila R, et al (2003). Breast cancer incidence 
and mortality trends in 16 European countries. Eur J Cancer, 
39, 1718-29.
Burman ML, Taplin SH, Herta DF, et al (1999). Effect of false-
positive mammograms on interval breast cancer screening 
in a health maintenance organization. 131, 1-6.
Chiarelli AM, Moravan V, Halapy E, et al (2003). False-positive 
result and reattendance in the Ontario Breast Screening 
Program. J Med Screen, 10, 129-33.
Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide 
burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 
127, 2893-917.
Gilliland FD, Rosenberg RD, Hunt WC, et al (2000). Patterns of 
mammography use among Hispanic, American Indian, and 
non-Hispanic White women in New Mexico, 1994-1997. 
Dongkwan Oh et al
Asian Pacific Journal of Cancer Prevention, Vol 12, 20112870
American journal of epidemiology, 152, 6.
Gram IT, Lund E, Slenker SE (1990). Quality of life following 
a false positive mammogram. Br J Cancer, 62, 1018-22.
Hofvind SS, Wang H, Thoresen S (2003). The Norwegian Breast 
Cancer Screening Program: re-attendance related to the 
women’s experiences, intentions and previous screening 
result. Cancer Causes Control, 14, 391-8.
Jemal A, Bray F, Center MM, et al (2011). Global cancer 
statistics. CA Cancer J Clin, 61, 69-90.
Johnson MM, Hislop TG, Kan L, et al (1996). Compliance with 
the screening mammography program of British Columbia: 
will she return? Can J Public Health, 87, 176-80.
Jung KW, Park S, Kong HJ, et al (2010). Cancer statistics in 
Korea: incidence, mortality and survival in 2006-2007. J 
Korean Med Sci, 25, 1113-21.
Katz SJ, Zemencuk JK, Hofer TP (2000). Breast cancer screening 
in the United States and Canada, 1994: socioeconomic 
gradients persist. American Journal of Public Health, 90, 
799-803.
Keegan TH, Gomez SL, Clarke CA, et al (2007). Recent trends in 
breast cancer incidence among 6 Asian groups in the Greater 
Bay Area of Northern California. Int J Cancer, 120, 1324-9.
Kim Y, Jun JK, Choi KS, et al (2011). Overview of the National 
Cancer screening programme and the cancer screening status 
in Korea. Asian Pac J Cancer Prev, 12, 725-30.
Lerman C, Trock B, Rimer BK, et al (1991). Psychological 
side effects of breast cancer screening. Health Psychol, 
10, 259-67.
Liberator P, Anderson J, Feiglin M, et al (1998). Molecular 
cloning and functional expression of mannitol-1-phosphatase 
from the apicomplexan parasite Eimeria tenella. J Biol Chem, 
273, 4237-44.
Lim SM, Lee HY, Choi KS, et al. (2010). Trends of mammography 
use in a national breast cancer screening program, 2004-
2008. Cancer Res Treat, 42, 199-202.
Lyon IARC: World Cacner Report  (2003). International Agency 
for Research on Cancer Press, 188-93.
Marcin JP, Schembri MS, He J, et al (2003). A population-based 
analysis of socioeconomic status and insurance status and 
their relationship with pediatric trauma hospitalization and 
mortality rates. Am J Public Health, 93, 461-6.
Marteau TM (1994). Psychology and screening: narrowing the 
gap between efficacy and effectiveness. Br J Clin Psychol, 
33, 1-10.
McCann J, Stockton D, Godward S (2002). Impact of false-
positive mammography on subsequent screening attendance 
and risk of cancer. Breast Cancer Res, 4, R11.
O’Byrne AM, Kavanagh AM, Ugoni A, et al (2000). Predictors 
of non-attendance for second round mammography in an 
Australian mammographic screening programme. J Med 
Screen, 7, 190-4.
O’Sullivan I, Sutton S, Dixon S, et al (2001). False positive 
results do not have a negative effect on reattendance for 
subsequent breast screening. J Med Screen, 8, 4.
O’Sullivan I, Sutton S, Dixon SP, N. (2001). False positive results 
do not have a negative effect on reattendance for subsequent 
breast screening. Journal of medical screening, 8, 4.
Pinckney RG, Geller BM, Burman M, et al (2003). Effect 
of false-positive mammograms on return for subsequent 
screening mammography. Am J Med, 114, 120-5.
Seigneurin A, Exbrayat C, Labarere J, et al (2011). Association 
of diagnostic work-up with subsequent attendance in a breast 
cancer screening program for false-positive cases. Breast 
Cancer Res Treat, 127, 221-8.
Smith RA, Cokkinides V, Brooks D, et al (2010). Cancer 
screening in the United States, 2010: a review of current 
American Cancer Society guidelines and issues in cancer 
screening. CA Cancer J Clin, 60, 99-119.
Smith RA, Saslow D, Sawyer KA, et al (2003). American Cancer 
Society guidelines for breast cancer screening: update 2003. 
CA Cancer J Clin, 53, 141-69.
Song L, Fletcher R (1998). Breast cancer rescreening in low-
income women. Am J Prev Med, 15, 6.
Won YJ, Sung J, Jung KW, et al (2009). Nationwide cancer 
incidence in Korea, 2003-2005. Cancer Res Treat, 41, 
122-31.
